Pfizer to Invest $500M in State-of-the-Art Gene Therapy Facility in North Carolina

 Pfizer to Invest $500M in State-of-the-Art Gene Therapy Facility in North Carolina

Pfizer to Invest $500M in State-of-the-Art Gene Therapy Facility in North Carolina

Shots:

  • Pfizer plans to invest half-billion dollars for the construction of its state-of-the-art gene therapy manufacturing facility in Sanford, North Carolina which is expected to support its ongoing R&D investments in gene therapy, like its R&D sites in Chapel Hill and Kit Creek
  • The investment will expand Pfizer’s footprints in Sanford, strengthen its gene therapy manufacturing technology and its ability to develop both clinical- and commercial-scale quantities of gene therapies for patients with rare diseases across the globe
  • Pfizer’s Sanford facility will manufacture gene therapies and its vaccine portfolio including Prevnar 13 and other vaccines currently present in Pfizer’s pipeline and will provide ~300 new jobs

Click here to­ read full press release/ article | Ref: Pfizer | Image: Behance

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post